Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The researchers intend to prospectively study the safety, clinical efficacy and microbial
outcomes in patients with recently diagnosed UC with FMT capsule therapy derived from
pre-defined donors. Donors will be specifically screened for Fusobacterium and Sutterella
species as well as for global diversity. It is unknown if treatment with antibiotics before
FMT improves the engraftment and/or efficacy of FMT in UC, therefore the researchers plan to
randomize subjects to receive pre-treatment with antibiotics or not before FMT therapy. The
research team enroll patients from The Susan and Leonard Feinstein IBD Center and our
established early diagnosis clinic at Mount Sinai Hospital (MSH).